OG RED HORN IMMUNITY SUPPORT INFUSED KRATOM:

Building on the groundbreaking research from Oregon State University** that revealed the virus-disrupting and inhibiting properties of CBDa and CBGa, we developed our Immune Support Blend. Krabot's Immune Support Blend is a complete, plant-based therapeutic driven by the addition of JuiceTiva™ (a water-soluble hemp additive) compounded with a total of 1500mg of Kratom per serving. Together, our Immune Support Blend adds multi-level engagement with layers of anti-bacterial and immunity-building properties to further combat viral infections and increase overall efficacy. The JuiceTiva™ additive from FarmTiva™ is a water-soluble hemp packed powder loaded with vitamins, Minerals, Omega 3 + 6, Polyphenols, Flavonoids, and Phytocannabinoids. Water solubility makes JuiceTiva™ 18X more bioavailable than standard CBD. Costing a whopping $500.00 per pound, we make it convenient and affordable.

Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants

Oregon State University Study

International Journal of Pharmaceuticals, Nutraceuticals and Cosmetic Science (2022) Vol 5(1) 33-47

Antimicrobial Activity of Secondary Metabolites Isolated from Endophytic Fungi Associated with Rubiaceae Species

IMMUNE SUPPORT INFUSED KRATOM DOSAGE

Introducing Krabot’s Immune Support Infused Kratom, we bring you CBDa / CBGa and Kratom capsules. Our Immunity Support capsules are available in increments of 60ct bottles. Both the powder and capsules contain 250mg of JuiceTiva™ per gram. 

• Lab tested for up to 17 different Cannabinoids
• Water-soluble Hemp
• 18X More Bioavailable than CBD
• Packed with Vitamins, Minerals, Omega 3+6, Polyphenols, Flavonoids, & Phytocannabinoids.
• Cold Pressed Hemp Powder
• Tested for Heavy Metal and Pesticides

Ingredients: Mitragyna Speciosa Leaf, JuiceTiva™ Cold Pressed Hemp Powder

**Van Breemen, Richard B. and Muchiri, Ruth N. and Bates, Timothy A. and Weinstein, Jules B. and Leier, Hans C. and Farley, Scotland and Tafesse, Fikadu G. “Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants”. ACS Publications. 10 January 2022.